英诺特(688253) - 2024 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2024 reached ¥281,611,655.58, representing a year-on-year increase of 109.36%[2] - Net profit attributable to shareholders was ¥146,085,284.93, up 171.44% compared to the same period last year[2] - The net profit after deducting non-recurring gains and losses was ¥137,138,047.10, reflecting a significant increase of 198.41%[2] - Basic and diluted earnings per share were both ¥1.07, marking an increase of 167.50% year-on-year[2] - Total operating revenue for Q1 2024 reached ¥281,611,655.58, a significant increase of 109.6% compared to ¥134,510,760.91 in Q1 2023[20] - Net profit for Q1 2024 was ¥146,085,284.93, up 171.5% from ¥53,818,215.08 in Q1 2023[21] - Basic and diluted earnings per share for Q1 2024 were both ¥1.07, compared to ¥0.40 in Q1 2023, an increase of 167.5%[22] Research and Development - Total R&D expenses amounted to ¥21,982,120.56, which is a 120.09% increase, indicating higher clinical trial costs[3] - R&D expenses accounted for 7.81% of total revenue, an increase of 0.38 percentage points[3] - Research and development expenses increased to ¥21,982,120.56 in Q1 2024, compared to ¥9,987,729.18 in Q1 2023, reflecting a growth of 120.5%[21] Assets and Liabilities - Total assets at the end of the reporting period were ¥2,177,077,741.61, a 5.39% increase from the end of the previous year[3] - Shareholders' equity attributable to the parent company was ¥1,989,554,539.71, up 8.01% from the previous year[3] - Total current assets amounted to RMB 1,976.78 million, an increase from RMB 1,872.62 million at the end of 2023[16] - The total assets of the company reached RMB 2,177.08 million, up from RMB 2,065.66 million at the end of 2023[16] - Total liabilities decreased to ¥187,523,201.90 in Q1 2024 from ¥223,646,680.00 in Q1 2023, a reduction of 16.2%[18] - The company's total equity rose to ¥1,989,554,539.71 in Q1 2024, compared to ¥1,842,008,497.63 in Q1 2023, an increase of 8.0%[18] Cash Flow - The company reported a net cash flow from operating activities of ¥124,003,396.25, with no comparative data available[2] - Cash flow from operating activities for Q1 2024 was ¥263,709,918.83, significantly higher than ¥52,359,899.45 in Q1 2023, marking an increase of 403.5%[24] - Cash received from operating activities totaled $271,290,079.16, a substantial increase from $61,843,262.67 in Q1 2023[25] - Total cash outflow from operating activities was $147,286,682.91, compared to $90,614,118.03 in the previous year, marking an increase of approximately 62.4%[25] - Net cash flow from operating activities for Q1 2024 was $124,003,396.25, a significant improvement compared to a negative cash flow of -$28,770,855.36 in Q1 2023[25] Market Strategy - The company is focusing on expanding its market presence in tiered medical systems and grassroots healthcare markets[14] - The company plans to continue enhancing its product offerings and technological advancements in response to market demands[14]